Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BDR in previously untreated Waldenstrom macroglobulinemia
2006-003563-31Phase 2Completed
- Sponsor
- European Myeloma Network
- Start
- Feb 2007
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics, Reversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of bortezomib, dexamethasone and rituximab in Waldenström macroglobulinemia (WM), sponsored by European Myeloma Network. Primary endpoint: Response rate. Started Feb 2007; status: completed.
02
Drugs
bortezomibdexamethasonerituximab
03
Conditions
Waldenström macroglobulinemia (WM)
Beyond the preview
Go deeper on 2006-003563-31.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-003563-31.